CD274 and non-small cell lung carcinoma: This is the first study to develop a comprehensive model that incorporates PD-L1, easily accessible clinical characteristics, serum parameters, and imaging features to predict the probability of PFS at 3, 6, and 12 months for NSCLC patients treated with ICIs plus chemotherapy.